Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions
CA 2501994 A1 · Owner: Torregrossa, Pascal · Inventors: Rougon, Genevieve; Schachner, Melitta; Torregrossa, Pascal
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues said peptide comprising a B epitope of a poly-.alpha.2,8 sialic acid attached to NCAM, which is recognized by an anti-poly-.alpha.2,8 sialic acid (PSA) antibody, for the preparation of a medicament for modulating NCAM functions to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions age-related learning and , memory problems and cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 16, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.